Ferring Pharmaceuticals issued the following announcement on March 5.
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, announced that it has entered into a feasibility development agreement with Ferring Pharmaceuticals to utilize Enteris' proprietary oral delivery platform, Peptelligence®, to develop an oral formulation of a peptide-based injectable therapeutic from Ferring.
Under the terms of the agreement, Enteris will conduct feasibility studies to develop an oral formulation of an undisclosed peptide therapeutic from Ferring. Based on the results of the feasibility program, Ferring will have the option to license the oral tablet formulation from Enteris. This new agreement between Enteris and Ferring adds to several ongoing projects between the two companies, including a licensing agreement announced in January 2017.
Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, remarked, "We are very pleased to extend our relationship with Ferring and explore the potential of Peptelligence to successfully enable the oral delivery of this peptide therapeutic. For Enteris, this latest agreement comes at time of significant growth as we continue to advance our internal pipeline, led by Ovarest®, and target additional opportunities to leverage the power of Peptelligence to enable the oral delivery of peptide-based medications that must otherwise be administered by injection."
Alan Harris, Senior Vice President, R&D Executive Office of Ferring Pharmaceuticals, said, "The oral delivery of peptides offers a significant opportunity to provide additional therapeutic choices to patients, while serving to maximize the market potential of peptide-based therapeutics. We continue to be impressed with Enteris' proprietary oral delivery technology and look forward to working with them on this new development program."
Original source can be found here.